African-Americans fare better in the short term following coronary interventions

Racial disparities in cardiovascular outcomes are well-established, however new findings from University of Pittsburgh researchers indicate that African-Americans fare better in the short term following coronary interventions.

Oscar Marroquin, M.D., assistant professor of medicine at the University of Pittsburgh School of Medicine, and colleagues studied the data of 3,692 white and 987 black patients enrolled in the multi-center National Heart Lung and Blood Institute Dynamic Registry who underwent coronary interventions between July 1997 and May 2004. Researchers compared the rates of myocardial infarction (heart attack), coronary bypass surgery, death and revascularization of patients at one-month, six-month and one-year intervals.

Paradoxically, despite having more adverse characteristics such as diabetes and high blood pressure, more acute myocardial infarction and less stent implantation, blacks were found to have a 70 percent lower risk of dying while in the hospital and better one- and six-month outcomes following their coronary interventions. However, the researchers found that after one year, the African-American patients no longer showed improved outcomes, pointing to the need for aggressive adherence to risk reduction recommendations.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients